35 Gatehouse Drive
27 articles with Skyhawk Therapeutics
Boehringer, Evotec and bioMérieux found Aurobac to combat antimicrobial resistance, Turnstone and Moffitt Expand TIL Collab, Skyhawk to gain potential $2B from Sanofi RNA splicing deal.
Companies to leverage Skyhawk's proprietary SkySTAR™ platform to discover and develop novel small molecules that modulate RNA splicing to address challenging oncology and immunology targets.
9/15/2021Ramping up after the Labor Day holiday, funds are flowing fast and free into these life science companies.
Skyhawk Therapeutics, Inc. announced that Fidelity Management & Research Company LLC has led a $133 million oversubscribed investment round in Skyhawk, along with other major investors.
Several biopharma companies announced Series B financing rounds or additional investment raises. Here’s a look.
Aragen Announces Partnership with Skyhawk Therapeutics, Aimed at Developing Novel Small Molecule Therapeutics that Correct RNA Expression
Aragen Life Sciences, a leading Contract Research and Development Organization, headquartered out of Hyderabad, India, announced that it has been selected by Skyhawk Therapeutics, a leader in the development of small molecule therapeutics that correct RNA expression, as its partner in India.
Skyhawk Therapeutics Expands Leadership Team, Appointing Elliot Ehrich MD as President and Graeme Smith PhD as SVP NonClinical Development
Elliot Ehrich MD brings 25+ years R&D and clinical development leadership experience to the company; Graeme Smith PhD DABT brings 15+ years of nonclinical drug development leadership experience to the company.
Skyhawk Therapeutics and Vertex Pharmaceuticals inked a strategic research collaboration and licensing deal focused on developing novel small molecules that modulate RNA splicing.
Skyhawk Therapeutics Expands Leadership Team with Chief Medical Officer and Head of Chemistry, and adds to its Scientific Advisory Board
Joseph Duffy PhD brings 20+ years of small molecule discovery chemistry and operations to his role as SVP Chemistry of Skyhawk Therapeutics, Elliot Ehrich MD brings 20+ years of clinical development for novel pharmaceuticals to his role as Chief Medical Officer of Skyhawk Therapeutics, and Rob Hershberg MD-PhD with 25+ years of biotech and pharma experience has jo
Skyhawk Therapeutics Announces Expansion of its Collaboration Agreement with Merck to Discover and Develop Novel Small Molecules that Modulate RNA Splicing
Skyhawk Therapeutics, Inc. announced that it has expanded its strategic collaboration with Merck, known as MSD outside the United States and Canada, to discover, develop and commercialize small molecules that modulate RNA splicing.
The two companies are working to develop and commercialize a particular type of therapy built on modulating RNA splicing using Skyhawk’s SkySTAR technology platform.
Experienced Business Leader in Biopharmaceutical Industry Joins as Chief Operating Officer at Skyhawk Therapeutics
Dr. Terrance Connolly brings over 20 years of biotech operations and business development experience to his role as Chief Operating Officer Skyhawk Therapeutics . WALTHAM, Mass. , Feb. 24, 2020 /PRNewswire/ -- Skyhawk Therapeutics, Inc. ("Skyhawk" or the "Company") today announced Dr. Terrance ("Terry") Connolly will become its Chief Operating Officer. Dr. Connolly w
Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that Modulate RNA Splicing
Skyhawk Therapeutics, Inc. (Skyhawk) today announced that it has entered into a second global strategic collaboration with an affiliate of Celgene Corporation (NASDAQ: CELG).
The company expands its Scientific Advisory Board with four additional RNA splicing, genetics, and disease experts, who join SAB Chair Professor Tyler Jacks & special advisor Professor Phil Sharp as well as several other internationally-recognized SAB members.
Skyhawk Therapeutics, Inc. ("Skyhawk"), today announced Dr. Phillip Sharp has joined as special advisor to its Scientific Advisory Board.
Skyhawk Therapeutics Announces Agreement with Genentech to Discover and Develop Small Molecule RNA Splicing Modifiers for Oncology and Neurodegenerative Diseases
Skyhawk will use its SkySTARTM platform to develop drug candidates directed to multiple targets for oncology and neurodegenerative diseases.
In a deal-making spree, Genentech will team up with the small companies to take on various diseases, including multiple sclerosis.
7/12/2019Biotech and pharma companies strengthen their leadership teams with new appointments.
Skyhawk to expand its collaboration with Biogen to develop novel small molecule RNA splicing modifiers for disease targets
Skyhawk Therapeutics Announces Collaboration Agreement with Merck to Discover and Develop Novel Small Molecules that Modulate RNA Splicing
Skyhawk will deploy its SkySTAR™ platform to develop drug candidates directed to multiple targets for neurodegenerative diseases and cancer